There are currently 75 active clinical trials seeking participants for Ulcerative Colitis research studies. The states with the highest number of trials for Ulcerative Colitis participants are Florida, California, Texas and New York.
CP101 for the Treatment of Ulcerative Colitis
NCT05852574
Recruiting
This is a dose ranging exploratory phase 1 pilot study to assess engraftment, safety, and efficacy of CP101, an oral microbiome therapeutic, in participants with active mild-to-moderate Ulcerative colitis. A total of 30 patients who meet eligibility criteria will be randomized 1:1 to either a short or extended induction dosing with CP101. An assessment of the microbiome will occur at baseline, Day 6, Week 4, Week 8, Week 12, Week 16, and Week 24.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Ulcerative Colitis
Register for Updates
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
NCT04767984
Recruiting
This phase II trial studies the effect of atorvastatin in treating patients with ulcerative colitis who have a dominant-negative missense P53 mutation and are at risk of developing large intestinal cancer. Patients with ulcerative colitis are known to have an increased risk of developing large intestinal cancer. Better ways to control ulcerative colitis and more knowledge about how to prevent colon cancer are needed. Atorvastatin is a drug used to lower the amount of cholesterol in the blood and... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/23/2024
Locations: Northwestern University, Chicago, Illinois +2 locations
Conditions: Ulcerative Colitis, Colorectal Carcinoma
Register for Updates
Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC)
NCT05466890
Recruiting
The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/08/2024
Locations: Del Sol Research Management, LLC, Tucson, Arizona +13 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
Register for Updates
ENhanced Recovery in CHildren Undergoing Surgery
NCT04060303
Recruiting
The institution of perioperative Enhanced Recovery Protocols (ERPs) has been found to decrease hospital length of stay, in-hospital costs, and complications among adult surgical populations but data in pediatric populations are lacking. The Assessing Effectiveness and Implementation of a Perioperative Enhanced Recovery Protocol for Children Undergoing Gastrointestinal Surgery, which has the short title "ENhanced Recovery In CHildren Undergoing Surgery (ENRICH-US)," study is a multicenter, pragma... Read More
Gender:
All
Ages:
Between 10 years and 18 years
Trial Updated:
01/04/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Register for Updates
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
NCT05019742
Recruiting
SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
11/24/2023
Locations: Clinical Research Associates, LLC, Huntsville, Alabama +15 locations
Conditions: Ulcerative Colitis
Register for Updates
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
NCT05666960
Recruiting
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/31/2023
Locations: University of Colorado School of Medicine, Aurora, Colorado +2 locations
Conditions: Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: Om Research, Lancaster, California +36 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
NCT05739162
Recruiting
The purpose of this research is to gather information on the safety and effectiveness of Endoscopic Sleeve Gastroplasty (ESG) for weight loss in a population of obese ulcerative colitis (UC) patients undergoing colectomy with eventual Ileal Pouch Anal Anastomosis (IPAA) compared to counseling on diet and lifestyle interventions alone.
Gender:
All
Ages:
Between 22 years and 69 years
Trial Updated:
10/18/2023
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Obesity, Ulcerative Colitis
Register for Updates
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
NCT04331639
Recruiting
The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.
Gender:
All
Ages:
Between 5 years and 25 years
Trial Updated:
10/09/2023
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
Register for Updates
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
NCT04314375
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
10/05/2023
Locations: Bausch Health Site 008, Garden Grove, California +3 locations
Conditions: Ulcerative Colitis
Register for Updates
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
NCT03847467
Recruiting
Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and well tolerated, while increasing fecal Bifidobacterium abundance and butyrate in a dose dependent manner. The investigators will test 1, 5, or 10 gm 2'-FL compared to 2 gm dextrose placebo as a daily dietary supplement in pediatric and young adult IBD participants in stable remission receiving inflixi... Read More
Gender:
All
Ages:
Between 11 years and 25 years
Trial Updated:
10/05/2023
Locations: Connecticut Children's Medical Center, Hartford, Connecticut +2 locations
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Register for Updates
The Role of Secondary Bile Acids in Intestinal Inflammation
NCT03724175
Recruiting
The cause of Inflammatory bowel disease (IBD) is unknown, but intestinal bacteria-involved in the production of molecules that impact health-are widely accepted to play a key role. A significant proportion of IBD patients with pouches (surgically created rectums after the diseased colon is removed) continue to have inflammation similar to their previous disease. Only a few microbes are known to have the capability to modify primary bile acids (PBAs) made by the liver to secondary bile acids (SB... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/03/2023
Locations: Stanford University, Stanford, California
Conditions: Ulcerative Colitis, Pouchitis
Register for Updates